Venture Capital

We advised BOM Capital with its investment in Gilde Healthcare IV, an investment fund investing in innovative medical technology companies, digital health and therapeutics in Europe and the US.

We advised LSP (Life Sciences Partners) with its investment in the Series B financing round of ViCentra, a company developing and commercializing an insulin pump system for diabetes patients.  With its Kaleido insulin pump, ViCentra aims to reduce the impact that diabetes can have on daily life. The syndicate, led by LSP with participation from existing investor INKEF, will invest EUR 10 million. The funding will support European commercialization of the Kaleido system and preparations for US market entry.

We advised Stichting DOEN with its investment in Zeewaar, a company that farms seaweed and produces and sells seaweed products.

We advised BOM Capital with its investment in Aglaia Oncology Fund II, an investment fund focusing on biomedical companies in the field of oncology.

We advised Stichting DOEN with its investment in Nederland Isoleert, a company that provides isolation for homes in the Netherlands by way of collective purchasing.

We advised BOM Capital with its investment in Dutch Venture Initiative, a fund-of-funds aiming to boost equity investments into innovative and/or high tech early and development stage enterprises in the Netherlands.